COMPANY UPDATE

Bangkok Chain Hospital PLC



Wednesday, March 30, 2016


BUY

Stock Data

| Last close (Mar 29) (Bt) | 10.60 |
|-----------------------------|-------|
| 12-m target price (Bt) | 12.00 |
| Upside (Downside) to TP (%) | 13.21 |
| Mkt cap (Btbn) | 26.43 |
| Mkt cap (US\$mn) | 748 |

| Bloomberg code | BCH TB |
|----------------------------|------------|
| Reuters code | BCH.BK |
| Risk rating | L |
| Mkt cap (%) SET | 0.20 |
| Sector % SET | 5.30 |
| Shares issued (mn) | 2,494 |
| Par value (Bt) | 1.00 |
| 12-m high / low (Bt) | 11.4 / 6.2 |
| Avg. daily 6m (US\$mn) | 1.61 |
| Foreign limit / actual (%) | 49 / 19 |
| Free float (%) | 38.2 |
| Dividend policy (%) | ≤ 40 |

Price Performance



Source: SET, SCBS Investment Research

Share performances

| | 1M | 3M | 12M | | | | | | |
|---------------------------------------|-----|------|------|--|--|--|--|--|--|
| Absolute | 7.1 | 17.1 | 31.7 | | | | | | |
| Relative to SET | 3.5 | 8.3 | 41.5 | | | | | | |
| Source: SET, SCBS Investment Research | | | | | | | | | |

Raweenuch Piyakriengkai Fundamental Investment Analyst on Securities (66-2) 949-1002 raweenuch.piyakriengkai@scb.co.th

Earnings rising, valuation discount to peers

The long wait for recovery is nearly over for BCH as it marches into a new growth cycle with 22% core earnings CAGR for the next three years. The World Medical Center (WMC) is making the turn from a drag to a driver as losses come down and is poised to generate profit as soon as 2018 – a year earlier than the previously expected 2019. Though earnings are on the way up, BCH is trading at 18x 2016 EV/EBITDA, below the regional average of 21x, and this comes down to 14x in 2018. We put BCH as our lead pick in the Thai healthcare sector.

WMC in the black as soon as 2018, not 2019. Yesterday's analyst meeting contained the good news that losses are less at high-end WMC, thus burdening BCH less and leading to earnings improvement. A positive development is the appointment of a new hospital director, Professor Adisorn Patradul M.D., in September last year, who is outlining a clear strategy path. WMC is developing "centers of excellence", ranging from cardiac, to orthopedics and advanced surgery, working closely with specialists from Chulalongkorn Hospital. It is working with governments and health agencies in several countries to bring in more international patients, a high-yield segment accounting for 38% of revenue in 2015, with the Middle East, China, Myanmar and Cambodia leading the list. This is bearing fruit, as seen in the 40% YoY rise in revenue to Bt321mn in 2015 and a cut in losses to Bt234mn from Bt287mn in 2014 - beating our estimate of Bt253mn. We believe these developments will continue and now expect WMC to show profit in 2018, ahead of the earlier forecast of 2019, though slower than management's guidance of 2017 as we are cautious with regards to the higher costs that will come from setting up these centers of excellence.

Rising SC revenue is on top. Growing revenue from the social security scheme (SC) will be another key driver for BCH. In 2016, BCH expects 120K additional insured persons (+17% YoY): 1) 20K at Kasemrad Sriburin Hospital after it returned to the program after leaving it in 2014, 2) 50K at Karunvej Rattanatibeth Hospital and 3) 50K at Kasemrad Chachoengsao Hospital. These additions will push SC revenue up 15% YoY to account for 38% of BCH's revenue in 2016.

Earnings upgrade. 22% EPS CAGR in 2015-18. We have raised earnings by 15% in 2016, 14% in 2017 and 13% in 2018 to factor in: 1) the earnings beat in 2015, 2) better operations at WMC with Bt163mn loss in 2016, Bt70mn loss in 2017 and then a profit of Bt38mn in 2018 (up from our previous forecast of losses of Bt182mn in 2016, Bt108mn in 2017 and Bt43mn in 2018) and 3) higher SC revenue. Our new forecast reflects a strong turnaround in earnings with a 22% CAGR for the next three years.

Valuation at a discount. BUY with end-2016 DCF TP at Bt12/share. Earnings are on the way up but BCH is trading at 18x 2016 EV/EBITDA, below the regional average of 21x – and it comes down to 14x in 2018. In our view, EV/EBITDA is better than PE as a comparative valuation as earnings are still being dragged down by losses at WMC (which are ending). We rate BUY with new end-2016 DCF TP of Bt12/share (from Bt10), consisting of Bt10.5/share for BCH excluding WMC and Bt1.5/share for WMC, and put the stock as our lead top pick in Thai healthcare sector, followed by BDMS.

Forecasts and valuation

| Year to 31 Dec | Unit | 2014 | 2015 | 2016F | 2017F | 2018F |
|------------------|--------|--------|-------|-------|-------|-------|
| Revenue | (Btmn) | 5,301 | 5,766 | 6,468 | 6,924 | 7,415 |
| EBITDA | (Btmn) | 1,423 | 1,468 | 1,654 | 1,840 | 2,055 |
| Core profit | (Btmn) | 522 | 527 | 662 | 803 | 956 |
| Reported profit | (Btmn) | 522 | 527 | 662 | 803 | 956 |
| Core EPS | (Bt) | 0.21 | 0.21 | 0.27 | 0.32 | 0.38 |
| DPS | (Bt) | 0.07 | 0.07 | 0.09 | 0.11 | 0.13 |
| P/E, core | (X) | 50.7 | 50.1 | 39.9 | 32.9 | 27.6 |
| EPS growth, core | (%) | (10.8) | 1.0 | 25.5 | 21.3 | 19.1 |
| P/BV, core | (x) | 5.7 | 5.4 | 5.0 | 4.6 | 4.1 |
| ROE | (%) | 11.3 | 11.0 | 13.0 | 14.5 | 15.7 |
| Dividend yield | (%) | 0.7 | 0.7 | 0.9 | 1.1 | 1.3 |
| EV/EBITDÁ | (x) | 21.1 | 20.0 | 17.7 | 15.3 | 13.7 |


Source: SCBS Investment Research

Tel. (662) 949-1000 Fax: (662) 949-1030 www.scbs.com Tel information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.


Financial statement

| Profit and Loss Statement (B | tmn) | | | | |
|--|-------------|-------------|------------------------------|---------------------|--------------|
| FY December 31 | 2014 | 2015 | 2016F | 2017F | 2018F |
| Total revenue | 5,301 | 5,766 | 6,468 | 6,924 | 7,415 |
| Cost of goods sold | (3,670) | (3,989) | (4,455) | (4,706) | (4,946) |
| Gross profit | 1,631 | 1,777 | 2,013 | 2,218 | 2,469 |
| SG&A | (721) | (855) | (936) | (985) | (1,028) |
| Other income | 80 | 86 | 119 | 124 | 130 |
| Interest expense | 160 | 163 | 170 | 141 | 148 |
| Pre-tax profit | 830 | 844 | 1,026 | 1,216 | 1,423 |
| Corporate tax | (159) | (174) | (205) | (243) | (285) |
| Equity a/c profits | - | 3 | 3 | 3 | 3 |
| Minority interests | (149) | (145) | (162) | (173) | (185) |
| Core profit | 522 | 527 | 662 | 803 | 956 |
| Extra-ordinary items | - | - | - | - | - |
| Net Profit | 522 | 527 | 662 | 803 | 956 |
| EBITDA | 1,423 | 1,468 | 1,654 | 1,840 | 2,055 |
| Core EPS (Bt) | 0.21 | 0.21 | 0.27 | 0.32 | 0.38 |
| Net EPS (Bt) | 0.21 | 0.21 | 0.27 | 0.32 | 0.38 |
| DPS (Bt) | 0.07 | 0.07 | 0.09 | 0.11 | 0.13 |
| Balance Sheet (Btmn) | | | | | |
| FY December 31 | 2014 | 2015 | 2016F | 2017F | 2018F |
| Total current assets | 1,933 | 2,137 | 2,479 | 2,683 | 2,787 |
| Total fixed assets | 7,557 | 7,859 | 7,931 | 7,974 | 8,017 |
| Total assets | 9,992 | 10,598 | 11,011 | 11,259 | 11,405 |
| Total loans | 4,031 | 3,662 | 3,648 | 2,648 | 2,648 |
| Total current liabilities | 1,803 | 3,042 | 3,118 | 4,344 | 4,868 |
| Total long-term liabilities | 3,324 | 2,510 | 2,511 | 1,012 | 13 |
| Total liabilities | 5,325 | 5,676 | 5,753 | 5,478 | 5,002 |
| Paid-up capital | 2,494 | 2,494 | 2,494 | 2,494 | 2,494 |
| Total equity | 4,667 | 4,922 | 5,258 | 5,781 | 6,404 |
| BVPS (Bt) Cash Flow Statement (Btmn) | 1.87 | 1.97 | 2.11 | 2.32 | 2.57 |
| FY December 31 | 2014 | 2015 | 2016F | 2017F | 2018F |
| Core Profit | 522 | 527 | 662 | 803 | 2018F 956 |
| | 433 | 461 | 457 | 483 | 484 |
| Depreciation and amortization Operating cash flow | 433 | 401 879 | 457 943 | 483 | 484 |
| Investing cash flow | (574) | (553) | (500) | (500) | (500) |
| Financing cash flow | (172) | 278 | (339) | (580) | (834) |
| Net cash flow | (327) | 367 | (33 <i>9</i>) 102 | (300) 101 | (034) (6) |
| Key Financial Ratios | (327) | 307 | 102 | 101 | (0) |
| | 2014 | 2015 | 2016F | 2017F | 2018F |
| Gross margin(%) | 30.8 | 30.8 | 31.1 | 32.0 | 33.3 |
| Operating margin(%) | 17.2 | 16.0 | 16.7 | 17.8 | 19.4 |
| EBITDA margin(%) | 26.8 | 25.5 | 25.6 | 26.6 | 27.7 |
| EBIT margin(%) | 18.4 | 17.2 | 18.2 | 19.3 | 20.8 |
| Net profit margin(%) | 9.8 | 9.1 | 10.2 | 11.6 | 12.9 |
| ROE (%) | 11.3 | 11.0 | 13.0 | 14.5 | 15.7 |
| ROA (%) | 5.2 | 5.1 | 6.1 | 7.2 | 8.4 |
| Net D/E (x) | 0.8 | 0.6 | 0.5 | 0.3 | 0.3 |
| Interest coverage (x) | 8.9 | 9.0 | 9.7 | 13.1 | 13.9 |
| | | 2.5 | | | |
| | 1.8 | 1.7 | 1.3 | 1.4 | 1.2 |
| Debt service coverage (x) Payout Ratio (%) | 1.8 33.4 | 1.7 33.1 | 1.3 35.0 | 1.4 35.0 | 1.2 35.0 |

| FY December 31 | <u>mn)</u> 4Q14 | 1Q15 | 2Q15 | 3Q15 | 4Q15 |
|-----------------------------|--------------------|--------|--------|---------|---------|
| Total revenue | 1,351 | 1,330 | 1,354 | 1,476 | 1,606 |
| Cost of goods sold | (935) | (940) | (984) | (1,012) | (1,053) |
| Gross profit | 415 | 390 | 370 | 465 | 553 |
| SG&A | (175) | (207) | (179) | (212) | (257) |
| Other income | 21 | 19 | 19 | 22 | 26 |
| Interest expense | 41 | 39 | 41 | 42 | 41 |
| Pre-tax profit | 221 | 163 | 168 | 232 | 281 |
| Corporate tax | (38) | (38) | (34) | (50) | (52) |
| Equity a/c profits | - | - | - | 2 | 0 |
| Minority interests | (39) | (30) | (36) | (41) | (38) |
| Core profit | 144 | 95 | 98 | 144 | 191 |
| Extra-ordinary items | - | - | - | - | - |
| Net Profit | 144 | 95 | 98 | 144 | 191 |
| EBITDA | 375 | 309 | 320 | 392 | 447 |
| Core EPS (Bt) | 0.06 | 0.04 | 0.04 | 0.06 | 0.08 |
| Net EPS (Bt) | 0.06 | 0.04 | 0.04 | 0.06 | 0.08 |
| Balance Sheet (Btmn) | | | | | |
| FY December 31 | 4Q14 | 1Q15 | 2Q15 | 3Q15 | 4Q15 |
| Total current assets | 1,933 | 1,974 | 1,960 | 1,871 | 2,137 |
| Total fixed assets | 7,557 | 7,557 | 7,153 | 7,845 | 7,859 |
| Total assets | 9,992 | 10,039 | 10,486 | 10,395 | 10,598 |
| Total loans | 4,006 | 4,007 | 4,413 | 4,502 | 4,452 |
| Total current liabilities | 1,803 | 2,545 | 3,047 | 3,009 | 3,042 |
| Total long-term liabilities | 3,300 | 2,500 | 2,500 | 2,500 | 2,500 |
| Total liabilities | 5,325 | 5,247 | 5,725 | 5,660 | 5,676 |
| Paid-up capital | 2,494 | 2,494 | 2,494 | 2,494 | 2,494 |
| Total equity | 4,667 | 4,792 | 4,761 | 4,734 | 4,922 |
| BVPS (Bt) | 1.87 | 1.92 | 1.91 | 1.90 | 1.97 |
| Main Assumptions | | | | | |
| | 2013 | 3 2014 | 2015 | 2016F | 2017F |
| Revenue breakdown (%) | | | | | |
| Cash service | 67 | 65 | 64 | 64 | 65 |
| | | | | | |
| Social securities (SC) | 32 | 2 34 | 35 | 35 | 34 |




12-Month Cumulative directors trade



Source: SET, SCBS Investment Research

Wednesday, March 30, 2016





Source: Company data and SCBS Investment Research

Figure 2: Regional valuation comparison

| | | | PE (x) | | EPS Growth (%) | | PBV (x) | | Div. Yield (%) | | ROE (%) | | EV/EBITDA (x) | | (x) | | | | |
|----------------------------|-------------|------|--------|------|----------------|------|---------|------|----------------|-----|---------|-----|---------------|------|------|------|------|------|------|
| Ticker | Country | 16F | 17F | 18F | 16F | 17F | 18F | 16F | 17F | 18F | 16F | 17F | 18F | 16F | 17F | 18F | 16F | 17F | 18F |
| Bangkok Chain Hospital * | Thailand | 39.9 | 32.9 | 27.6 | 25.5 | 21.3 | 19.1 | 5.0 | 4.6 | 4.1 | 0.9 | 1.1 | 1.3 | 13.0 | 14.5 | 15.7 | 17.7 | 15.3 | 13.7 |
| Bangkok Dusit Medical* | Thailand | 39.3 | 33.8 | 29.6 | 14.7 | 16.2 | 14.0 | 6.1 | 5.6 | 5.1 | 1.3 | 1.5 | 1.7 | 15.6 | 17.2 | 17.9 | 23.5 | 20.6 | 18.3 |
| Bumrungrad Hospital* | Thailand | 39.9 | 35.7 | 31.4 | 11.6 | 11.6 | 13.8 | 10.4 | 9.0 | 8.0 | 1.3 | 1.4 | 1.6 | 27.3 | 26.9 | 27.0 | 25.1 | 22.4 | 19.6 |
| Chularat Hospital | Thailand | 40.9 | 35.0 | 28.3 | 32.7 | 16.9 | 23.7 | 8.9 | 8.2 | 6.9 | 1.2 | 1.5 | 2.3 | 21.2 | 22.9 | 25.4 | 28.4 | 24.0 | 20.0 |
| Ladprao General Hospital | Thailand | 31.9 | 26.4 | 25.7 | 28.2 | 20.6 | 2.7 | 3.2 | 3.0 | 2.8 | 2.0 | 2.7 | 2.0 | 10.3 | 11.9 | 11.7 | 21.3 | 18.7 | 15.9 |
| Vibhavadi Medical Center | Thailand | 45.3 | 38.9 | 34.0 | 2.6 | 16.7 | 14.3 | 5.6 | 5.2 | 4.7 | 1.5 | 1.7 | 1.8 | 15.7 | 17.1 | 18.0 | 22.8 | 20.4 | 18.3 |
| KPJ Healthcare Bhd | Malaysia | 28.4 | 24.6 | 22.3 | 15.8 | 15.5 | 10.5 | 2.9 | 2.7 | 2.5 | 1.8 | 2.0 | 2.2 | 10.2 | 10.8 | 11.9 | 14.1 | 12.5 | 11.0 |
| IHH Healthcare Bhd | Malaysia | 48.8 | 40.6 | 35.1 | 16.9 | 20.3 | 15.6 | 2.4 | 2.3 | 2.2 | 0.6 | 0.6 | 0.7 | 5.0 | 5.8 | 6.4 | 23.7 | 20.6 | 18.4 |
| Raffles Medical Group | Singapore | 33.2 | 29.3 | 24.8 | 11.9 | 13.2 | 18.2 | 3.9 | 3.6 | 3.3 | 1.4 | 1.5 | 1.6 | 12.4 | 13.0 | 14.4 | 24.2 | 21.1 | 18.2 |
| Apollo Hospitals Enterpris | India | 41.4 | 32.7 | 21.4 | 21.6 | 26.5 | 52.8 | 4.9 | 4.4 | 3.8 | 0.5 | 0.7 | 1.1 | 12.2 | 13.7 | 19.0 | 20.6 | 17.3 | 12.7 |
| Ramsay Health Care | Australia | 24.0 | 21.7 | 19.8 | 14.9 | 10.5 | 9.7 | 5.7 | 5.0 | 4.6 | 2.2 | 2.4 | 2.6 | 23.6 | 23.3 | 22.6 | 11.8 | 11.0 | 10.2 |
| Ryman Healthcare | New Zealand | 23.9 | 20.7 | 18.2 | -1.4 | 15.5 | 14.0 | 3.0 | 2.6 | 2.4 | 2.1 | 2.4 | 2.8 | 14.4 | 13.7 | 14.2 | 17.8 | 14.8 | 14.8 |
| | Average | 36.4 | 31.0 | 26.5 | 16.2 | 17.1 | 17.4 | 5.2 | 4.7 | 4.2 | 1.4 | 1.6 | 1.8 | 15.1 | 15.9 | 17.0 | 20.9 | 18.2 | 15.9 |

Source: Bloomberg

*SCBS estimates

CG Rating 2015 Companies with CG Rating

ADVANC, BAFS, BCP, BIGC, BTS, CK, CPN, DRT, DTAC, DTC, EASTW, EGCO, GRAMMY, HANA, HMPRO, INTUCH, IRPC, IVL, KBANK, KCE, KKP, KTB, LHBANK, LPN, MCOT, MINT, MONO, NKI, PHOL, PPS, PS, PSL, PTT, PTTEP, PTTGC, QTC, RATCH, ROBINS, SAMART, SAMTEL, SAT, SC, SCB, SCC, SE-ED, SIM, SNC, SPALI, THCOM, TISCO, TKT, TMB, TOP, VGI, WACOAL

AAV, ACAP, AGE, AHC, AKP, AMATA, ANAN, AOT, APCS, ARIP, ASIMAR, ASK, ASP, BANPU, BAY, BBL, BOMS, BEM, BKI, BAL, BOL, BROOK, BWG, CENTEL, CFRESH, CHO, CIMBT, CM, CNT, COL, CPF, CPI, CSL, DCC, DELTA, DEMCO, ECF, EE, ERW, GBX, GC, GFPT, GLOBAL, CHURUL, HOTPOT, HYROR, ICE, ILI, IIINT, IRC, KAK, KASP, BANPU, BAY, BBL, BOMS, BEM, BKI, BA, BOL, BROOK, BWG, CENTEL, CFRESH, CHO, CIMBT, CM, CNT, COL, CPF, CPI, CSL, DCC, DELTA, DEMCO, ECF, EE, ERW, GBX, GC, GFPT, GLOBAL, CHURUL, HOTPOT, HYROR, ICE, ILI, IIINT, IRC, KAK, KASP, BANPU, BAY, BBL, BOMS, BEM, BKI, BA, BOL, BROOK, BWG, CENTEL, CFRESH, CHO, CIMBT, CM, CNT, COL, CPF, CPI, CSL, DCC, DELTA, DEMCO, ECF, EE, ERW, GBX, GC, GFPT, GLOBAL, CHURUL, HOTPOT, HYROR, ICE, ILINT, INT, INT, TINT, INT, THOT, INTE, THAL, SMK, SMPC, SMF, SH, SSF, SSI, SSSC, SST, STA, STEC, SWI, SWC, SYMC, SYMTEC, TASCO, TBSP, TCAP, TF, TGCI, THAI, THANA, THANI, THIP, THRE, THREL, TICON, TIP, TIPCO, TK, TKS, TMI, TMILL, TMT, TNDT, TNITY, TNL, TOG, TPC, TRCORP, TRC, TRU, TRUE, TSC, TSTE, TSTH, TTA, TTCL, TTW, TU, TVD, TVO, TWPC, UAC, UT, UV, VNT, WAVE, WINNER, YUASA, ZMICO

25, AEC, AEONTS, AF, AH, AIRA, AIT, AJ, AKR, AMANAH, AMARIN, AP, APCO, AQUA, AS, AIA, AUCT, AYUD, BA, BEAUTY, BEC, BFIT, BH, BIG, BJC, BJCHI, BKD, BTNC, CBG, CGD, CHG, CHOW, CI, CITY, CKP, CNS, CPALL, CPL, CSC, CSP, CSS, CTW, DNA, EARTH, EASON, ECL, EFORL, ESSO, FE, FIRE, FOCUS, FORTH, FPI, FSMART, FSS, IVC, GCAP, GENCO, CL, GLAND, GLOW, GOLD, GYT, HTC, HTECH, IEC, IFEC, IFS, IHL, IRCP, TD, JSP, JTS, JUBILE, KASET, KBS, KCAR, KGI, KKC, KTIS, KWC, KYE, L&E, LALIN, LHK, LIT, TT, LST, M, MJOR, MAKRO, MATCH, MATI, MBKET, M-CHAI, MFC, MILL, MUD, MK, MODDEN, MRONG, MFG, MSC, MTI, MTLS, NC, NOK, NUSA, NWR, MYT, OCEAN, PACE, PATO, PB, PCA, PCSGH, PDG, PF, PICO, PL, PLANB, PLAT, PPM, PRG, PRIN, PSTC, PTL, PTU, PTU, TLI, TIW, TLUXE, TMC, TMD, TOPP, TPCH, TPIPL, TRT, TSE, TSR, UMI, UP, UPG, UPER, LAUWC, VIBHA, VIH, VPO, WHA, WIN, XO **Corporate Governance Repot** The disclosure of the survey result of the Thai Institute of Directors Association (10DP) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the 10D is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not base on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thail Listed Companies. As a result, the survey result may be changed after that date. SCB Securities Company Limited does not conform nor certify the accuracy of such survey result.

Anti-corruption Progress Indicator 2015 Level 5: Extended (@urumaaj@filduraia) BCP, CPN, CYT, IEEC, PE, PM, PPP, PT, PTT, PTTGC, SAT, SCC, THANI, TOP Level 4: Certified (fairumaaj@filduraia) ADVANC, AMANAH, ASP, AYUD, BATS, BANPU, BAY, BBL, BKI, BLA, BTS, CFRESH, CIMBT, CNS, CSL, DCC, DRT, DTC, EASTW, ECL, EGCO, ERW, FSS, GCAP, HANA, HTC, INTUCH, IRPC, IVL, KBANK, KCE, KGI, KKP, KTB, LANNA, LHBANK, MBKET, MFC, MINT, MTI, NKI, PPS, PSL, PTG, PTTEP, SABINA, 2058, SINGER, SIS, SSS, SNU, TCAP, THCOM, THRE, THREL, TISCO, TMB, TMD, TNITY, TOG, TSTH Level 38: Established by Commitment and Policy (furaesn'stilaafu eruinitaafu erui

Nature, Markin, Martin, Molzen, Markin, Marte, Markin, Markin, Markin, Markin, Markin, Martin, Mart

Anti-corruption Progress Indicator The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment the assessment in received from the listed company, as stipulated in the form for the assessment of Anti-Corruption which refers to the Annual Registration Statement (form 56-1), Annual Report (form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operations and is not based on any inside information. Since this assessment the only the assessment result. Is of the assessment result. It may be changed after that date or when there is any change to the relevant information. Nevertheless, SCB Securities Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment result.

Level 5: Extended – Extension of the anti-corruption policy to business partners in the supply chain, and disclosure of any current investigations, prosecutions or closed cases Level 4: Certified – Audit engagement by audit committee or auditors approved by the office of SEC, and receiving certification or assurance by independent external assurance Level 3: Established – Carrying out preventive measures, risk assessment, communication and training for all employees, including consistent monitoring and review processes Level 3: Established – Carrying out preventive measures, risk assessment, communication and training for all employees, including consistent monitoring and review processes

rnal assurance providers (CAC etc.)

Level 3: Established > Gartying due prevenitive ineasies, risk assessment, continuantiand and unamound on an empoyees, including consistent information and reverse p Level 3: Established by declaration of intent, Level 38: Established by Commitment and Policy Level 2: Declared – Public declaration statement to participate in Thaland's private sector Collective Action Coalition Against Corruption (CAC) or equivalent initiatives Level 2: Declared – Public declaration statement to participate in Thaland's private sector Collective Action Coalition Against Corruption (CAC) or equivalent initiatives Level 1: Committed – Organizations statement or board's resolution low ork against corruption and to be in compliance with all relevant laws

